🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

FABTECH TECHNOLOGIES LTD FABTECH NSEPHARMA

Healthcare · Health Information Services · India
https://www.fabtechnologies.com
Company Profile ↓
₹159.54
-12.53% 1Y
Mkt Cap₹709.17 Cr
P/E15.95
P/B1.45
52W High₹255.41
52W Low₹133.90
Book Value₹94.43
EPS (TTM)₹10.00

Company Overview

Fabtech Technologies Limited operates as a biopharma engineering company that provides aseptic manufacturing facilities internationally. The company offers designing, engineering, procurement, installation, and testing of pharmaceutical equipment. It serves pharmaceuticals, biotech, and healthcare companies. The company was founded in 2001 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 20.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 28.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 15.9, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Mar 2026 Revenue of ₹410.77 Cr (+25.7% YoY); net profit ₹38.36 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +25.8%, earnings -17.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 28.5%, profit CAGR 20.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:28.45%
1 Year:25.75%

Compounded Profit Growth

5 Years:20.85%
1 Year:-17.43%

Stock Price Performance

1 Year:-12.53%
6 Months:-16.27%
3 Months:+1.73%
1 Month:+0.70%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 21% of range
₹133.90 ₹255.41
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)53.61 · Neutral
Price Performance
1M+0.70%
3M+1.73%
6M-16.27%
1Y-12.53%
Valuation vs Sector

P/E of 15.95 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 28.5% over 5 years.
  • Profit CAGR of 20.8% over 5 years.

CONS

  • Trading 37.5% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
15.95
Industry PE
39.97
Forward P/E est.
19.32
PEG Ratio
-
Book Value
₹94.43
Price to Book
1.45
P/S
1.71
EV/EBITDA
12.04
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
28.45%
Profit 5Y
20.85%
Revenue (YoY)
25.75%
Earnings (YoY)
-17.43%

Profitability & Returns

ROCE
11.73%
ROE
9.14%
ROA
5.87%
Profit Margin
9.34%
Op Margin
7.23%
Gross Margin
40.95%
EPS (Latest Qtr)
₹5.75
EPS (TTM)
₹10.00

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
2.42
Current Ratio
2.52
Debt
₹69.63 Cr
Total Assets
₹653.70 Cr
Current Assets
₹522.05 Cr
Working Capital
₹315.21 Cr

Ownership

Promoter Holding
72.46%
Chg in Prom Hold
3.52%
FII / Inst Holding
1.17%
Chg in FII Hold
-1.06%

Financial Snapshot

Enterprise Value
₹709.17 Cr
Total Revenue (TTM)
₹410.77 Cr
EBITDA
₹57.73 Cr
Free Cash Flow
₹-4.23 Cr
Operating Cash Flow
₹47.74 L
Shares Outstanding
₹4.45 Cr
Gross Margin
40.95%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FABTECH FABTECH TECHNOLOGIES LTD NSEPHARMA 159.54 15.95 ₹709.17 Cr 0.00% 11.73% 9.14% 28.45% 20.85%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 59.00 Cr104.32 Cr134.86 Cr68.00 Cr121.00 Cr62.76 Cr158.52 Cr
Cost of Revenue -53.65 Cr77.38 Cr--40.93 Cr103.20 Cr
Gross Profit -50.66 Cr57.48 Cr--21.83 Cr55.33 Cr
Operating Expenses 54.00 Cr28.48 Cr39.75 Cr74.00 Cr91.00 Cr34.60 Cr34.40 Cr
Operating Income 4.00 Cr22.18 Cr17.73 Cr-7.00 Cr29.00 Cr-12.77 Cr20.92 Cr
EBITDA 5.00 Cr24.62 Cr21.65 Cr-6.00 Cr30.00 Cr-4.50 Cr32.06 Cr
Interest Expense 042.53 L1.09 Cr1.00 Cr1.00 Cr87.39 L87.64 L
Pretax Income 6.00 Cr23.51 Cr19.93 Cr-6.00 Cr31.00 Cr-6.68 Cr29.89 Cr
Tax Provision 90.00 L3.05 Cr4.83 Cr6.00 L3.10 Cr-1.01 Cr7.84 Cr
Net Income 5.00 Cr20.46 Cr15.09 Cr-6.00 Cr28.00 Cr-5.68 Cr22.06 Cr
Diluted EPS 1.584.603.39-1.898.68-1.565.75

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 133.00 Cr121.00 Cr257.00 Cr193.80 Cr226.14 Cr326.67 Cr410.77 Cr
Cost of Revenue ---91.64 Cr121.51 Cr181.86 Cr242.56 Cr
Gross Profit ---102.15 Cr104.62 Cr144.81 Cr168.21 Cr
Operating Expenses 119.00 Cr110.00 Cr225.00 Cr81.43 Cr69.29 Cr109.72 Cr138.51 Cr
Operating Income 14.00 Cr11.00 Cr30.00 Cr20.72 Cr33.53 Cr35.09 Cr29.70 Cr
EBITDA 14.00 Cr11.00 Cr32.00 Cr32.38 Cr39.75 Cr65.14 Cr57.73 Cr
Interest Expense 2.00 Cr2.00 Cr3.00 Cr2.58 Cr1.90 Cr2.10 Cr4.16 Cr
Pretax Income 16.00 Cr11.00 Cr31.00 Cr27.90 Cr35.77 Cr60.43 Cr48.27 Cr
Tax Provision 4.32 Cr3.19 Cr7.75 Cr6.17 Cr8.55 Cr13.98 Cr9.92 Cr
Net Income 12.00 Cr8.00 Cr23.00 Cr21.73 Cr27.22 Cr46.45 Cr38.36 Cr
Diluted EPS 12,390.008,040.0084.28--10.4510.00

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 123.00 Cr126.00 Cr172.00 Cr213.86 Cr269.24 Cr426.56 Cr653.70 Cr
Current Assets ---181.42 Cr241.16 Cr314.04 Cr522.05 Cr
Cash & Equivalents ---6.34 Cr26.84 Cr8.67 Cr86.88 Cr
Inventory ---17.24 Cr29.27 Cr59.42 Cr21.34 Cr
Receivables ---99.41 Cr96.66 Cr150.74 Cr204.34 Cr
Total Liabilities ---124.90 Cr137.35 Cr253.44 Cr233.93 Cr
Current Liabilities ---122.35 Cr134.89 Cr225.47 Cr206.85 Cr
Long Term Debt ---86.47 L27.68 L53.44 L53.02 L
Total Debt 1.00 Cr9.00 Cr21.00 Cr35.45 Cr12.71 Cr83.83 Cr69.63 Cr
Total Equity 38.01 Cr46.01 Cr68.00 Cr88.96 Cr131.88 Cr173.11 Cr419.77 Cr
Shares Outstanding ---4.45 Cr4.45 Cr4.45 Cr4.45 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 64.00 Cr-9.00 Cr-3.00 Cr-13.89 Cr60.43 Cr-36.14 Cr47.74 L
Investing Cash Flow -28.00 Cr4.00 Cr-9.00 Cr1.89 Cr-30.00 Cr-20.05 Cr-112.31 Cr
Financing Cash Flow -23.00 Cr6.00 Cr8.00 Cr11.97 Cr-11.96 Cr36.26 Cr189.66 Cr
Capital Expenditure 00-1.00 Cr-32.37 L-1.22 Cr-24.78 Cr-4.71 Cr
Free Cash Flow 64.00 Cr-9.00 Cr-4.00 Cr-14.21 Cr59.21 Cr-60.93 Cr-4.23 Cr
Net Change in Cash 13.00 Cr1.00 Cr-4.00 Cr-2.92 L18.46 Cr-19.94 Cr77.83 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---52.7%46.3%44.3%40.9%
Operating Margin % 10.5%9.1%11.7%10.7%14.8%10.7%7.2%
Net Margin % 9.0%6.6%8.9%11.2%12.0%14.2%9.3%
ROE % 31.6%17.4%33.8%24.4%20.6%26.8%9.1%
ROCE % ---22.6%25.0%17.4%6.6%

Shareholding Pattern

Insiders
72.46%
Institutions
1.17%
Public Float
4.25%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FABTECH

Google News Sat, 15 Nov 2025

FABTECH Stock Price and Chart — NSE:FABTECH - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBJUUhXbU41UGZVWmxfQ2U4X29pOVVHdnpiUVB5U2RvanRVb09ZbTgyNkVSek5QNjhDaVQ0eFZLQnNSQ2FvUTJtcDFSQzdSVDJEajhEMGFraXJFZUdq?oc=5" target="_blank">FABTECH Stock Price and Chart — NSE:FABTECH…

Google News ue, 16 Jun 2026

Momentum Stocks: Fabtech Tech, Arvind Smart, Vdeal System rally up to 16% on sheer momentum - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNNnFucTFaRm42bzBsMmQ3Q1ZkUVZqNm5EaXFzaFloaVBQTU81cEx1MVpMUno4NjQwQVhscUZqclpuTjlpRl9KZkJoNjN4d2pkUk1CWmRlNHFySXZKOWh2MFE2YUF0SWFDU2RoaXJCNE1kQVctcVA5N2hTYkhHbzZ1VWwxT3Iza09fVVVEMj…

Google News Mon, 15 Jun 2026

Fabtech Technologies confirms no encumbrance on promoter shares in FY26 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQTDducEg2ckRWY2MwMXNsTklnRTduN0dSU3l4X0FoODJrdC1BOGVMWGxzUzdIdXZCYi1HYzJ5cHNiZnhmeElScV9RZGEzeEp2NENpTWIwUlEzZktUSnRyTFB4d3RPdkNtSkVtQ2Y4aFRrdFo4dWFocm4ycWl5VFJwME90XzBqQmRQZGFCOF…

Google News Wed, 10 Dec 2025

Why is Fabtech Technologies' Cleanrooms Share Price Rising - Equitymaster

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQTEdzdEZ1ZTdtQ2xJV21xQ0FEaEVpd3BhWjhaVUNZZldmMWQwM2wwYnZIdjRXdHhjdGxGeU9fa0pxT1lJUGgtbmQ3YkMtRU9RVnBka1NZNjNmOEw5Z1R6RWZHQmRobmRrLUJlZE83X2IzaVhYcXhtOHlBNEt3OTZiUkFFYjV4YkR3TUJqVz…

Google News ue, 07 Oct 2025

Fabtech Technologies shares list flat at IPO price of Rs 191 on exchanges - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOd2p6SFBXT2QyVmNaTWJJVWFjTHc1cGp5RFJVOWhsLUpQVFlza09makpkREN0TzNfSHRxMV84LWNGQzVOVTE5bkIyUFg0QTBreG13UjBwZ2lJUC1XTmpLbHQzX0xPMXhsY1R2Y3B2cG9CVGJITXBadHlpRU45N1d3MWk4a1BsWmk4Vm5VOT…

Google News ue, 28 Apr 2026

Fabtech Technologies surges after PAT rises over 46% YoY in Q4 - Business Standard

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOWVhOeWNUZWtOUmp0QVN0T0ZsT3N2WWIzRUZFT3E1UnhONGdhTHJyMjFnejB5Yk91cFZiZldRcTh3b2N2MGtzNzFJaVdmUWlZNHVpOHRsejhZbnh5TU1DZ1JTXzllLWVPWWh2MmZ3MlVxSGRHN1hWRzZFdlM0MlU1dEhTWnhqckw3VWR1UU…

FABTECH — Frequently Asked Questions

What is the current share price of FABTECH TECHNOLOGIES LTD (FABTECH)?

As of 2026-07-15 09:52 IST, FABTECH TECHNOLOGIES LTD (FABTECH) trades at ₹159.54 on NSE. Its 52-week range is ₹133.90 to ₹255.41.

What is the market capitalisation of FABTECH?

FABTECH TECHNOLOGIES LTD (FABTECH) has a market capitalisation of ₹709.17 Cr on NSE.

What is the P/E ratio of FABTECH?

FABTECH trades at a trailing price-to-earnings (P/E) ratio of 15.95. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.45.

What is the return on equity (ROE) of FABTECH?

FABTECH has a return on equity (ROE) of 9.14%. Its return on capital employed (ROCE) is 11.73%.

Is FABTECH a good stock to buy?

This page provides a data-driven analysis of FABTECH TECHNOLOGIES LTD (FABTECH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space